Business Wire

EUROSETS

17.7.2024 11:13:26 CEST | Business Wire | Press release

Share
Eurosets: Newborn baby saved from acute bronchiolitis in Martinique by Colibri third-generation life-support device

The baby was affected by a viral infection, leaving him unable to breathe. Thanks to a state-of-the-art device, used for the first time in the world in the Caribbean, the medical-surgical team was able to save the infant.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716825866/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Colibrì, the lightest life-saving device that replaces the function of the heart and lungs (Photo: Eurosets)

The Colibri (hummingbird), one of the national symbols of Martinique, is also the name of an innovative, next-generation ECMO system, designed and manufactured by Eurosets, an Italian company based in the biomedical district of Medolla (MO), which enabled the medical-surgical team at Martinique University Hospital to save the life of a one-and-a-half-month-old child suffering from acute bronchiolitis.
The baby was born in Guadeloupe and weighed just 5kg. He was unable to breathe independently due to the viral infection, which subsequently led to heart failure. The infant was immediately transferred to the CHU de Martinique (CHUM), the only French hospital in the Caribbean with a third-level pediatric intensive care unit but, due the child's unstable condition, it was impossible to move him.
Following first-rate coordination with the neonatal intensive care unit at Guadeloupe University Hospital, the Martinique team from the UMAC (Unité Mobile d'Assistance Circulatoire) was able to travel to the neighboring island and connect the new ECMO system in the jugulo-carotid position to the newborn, allowing the infant to be transferred safely by helicopter.
The procedure was a success thanks to the seamless cooperation between Dr Xavier Beretta-Piccoli, pediatric intensive care specialist, and Dr Fabio Cuttone, head of pediatric cardiac surgery at the CHUM.
This intervention marked the world's first installation of a third-generation transportable device entirely designed and adapted for infants and children. The UMAC 972, consisting of a medical (intensive care specialist, cardiac surgeon) and paramedical (perfusionist) team, a pioneer in mobile circulatory assistance in the Caribbean archipelago and unique in terms of know-how and experience, played a vital role in the success of this medical treatment.
The infant was admitted to the CHUM pediatric intensive care unit. He received care and was attached to Colibri for five days until his lungs and heart functioned normally. Subsequently, having fully recovered from his bronchiolitis, the child was discharged from hospital and returned to Guadeloupe after 15 days in hospital. He will have to be monitored periodically, like all babies who have been in intensive care. He is now out of danger.

This ground-breaking treatment, the result of cooperation between the Martinique University Hospital, Eurosets, the CTM (Collectivité Territoriale de la Martinique) and European funding from React-UE (Recovery assistance for cohesion and the territories of Europe), finally provides the children of the Caribbean archipelago with a life-saving strategy at the forefront of technology.
Colibri is the world's lightest life-saving device capable of temporarily replacing cardiac and pulmonary functions. It is the only third-generation transportable system entirely designed and adapted to newborns and children.
In addition to adult patients, the device can be used on pediatric or even neonatal patients thanks to a dedicated centrifugal pump. The technology is suitable for use in a variety of therapeutic applications, including extracorporeal cardiopulmonary resuscitation (E-CPR) in cardiac arrest, extracorporeal membrane oxygenation (ECMO) and mechanical circulatory support (MCS).

Equipped with a centrifugal pump with magnetic levitation and a device capable of artificially oxygenating the blood, as well as offering excellent ergonomics, the Colibri is a high-performance circulatory assistance system, ideal in all situations in which intra- and extra-hospital transportability are crucial, including the most extreme rescue operations, such as airborne medical evacuations (by helicopter, passenger airline or military aircraft), scenarios that are common in the Caribbean region.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be crossreferenced with the source-language text, which is the only version of the text intended to have legal effect.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716825866/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 08:00:00 CEST | Press release

Endotronix co-founder and former CEO joins VahatiCor as the company advances the A-FLUX Reducer System® and the SERRA-I early feasibility study VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed o

Modon Partners With Montage Hotels & Resorts to Bring Ultra-Luxury Hospitality Brand to Egypt’s Ras El Hekma17.5.2026 13:53:00 CEST | Press release

Montage Ras El Hekma introduces the first branded residences for purchase at the Mediterranean destination, alongside the region’s first Montage resort Abu Dhabi-based Modon Holding and Montage Hotels & Resorts have announced Montage Ras El Hekma, which will introduce the first branded residences for purchase at Ras El Hekma on Egypt’s Mediterranean coast. This is the first Montage resort in Egypt – supporting the emerging city’s growth as a global hub for leisure, business and tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517167234/en/ Modon partners with Montage Hotels & Resorts to bring ultra-luxury hospitality brand to Egypt’s Ras El Hekma (Photo: AETOSWire) Montage Ras El Hekma will feature 200 guestrooms and suites, in addition to 96 Montage Residences, and will offer a curated mix of wellness and leisure amenities, including beachfront swimmable lagoons, a Spa Montage with 13 treatment rooms, and six dini

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center17.5.2026 08:00:00 CEST | Press release

Compact, vault-integrated platform selected through a competitive European tender will bring proton therapy to patients across Southern Italy. Mevion Medical Systems, the global leader in compact proton therapy, today announced that it has been selected to deliver the MEVION S250-FIT Proton Therapy System™ to Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples. The award, made following a competitive European tender, will establish the first proton therapy center in Southern Italy, significantly expanding access to advanced radiation therapy for patients across the region and reducing the need for patients to travel long distances to northern Italy for care. Until now, proton therapy in Italy has only been available at centers located in Northern Italy, requiring patients from Southern Italy to travel significant distances for care. The Pascale project supports a broader strategy to establish Naples as a leading oncology hub and to improve healthcare equity across Italy. “T

TetraMem Announces 22nm Multi-Level RRAM Analog In-Memory Computing SoC Milestone16.5.2026 10:43:00 CEST | Press release

TetraMem Inc., a Silicon Valley–based semiconductor company developing analog in-memory computing (IMC) solutions, today announced the successful tape-out, manufacturing, and initial silicon validation of its MLX200 platform, a 22nm multi-level RRAM-based analog IMC system-on-chip (SoC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260516556464/en/ Photograph of the MLX200 chip with a five-cent coin for size reference The achievement marks a significant step toward the commercialization of analog computing architectures based on emerging non-volatile memory technologies, addressing the growing challenges of data movement, power consumption, and thermal constraints in modern AI systems. As AI workloads continue to scale, system performance is increasingly constrained by the cost of moving data between memory and compute units. Analog in-memory computing offers a fundamentally different approach by performing computation dir

STARTEEPO Invest Announces 5% Stake in Xerox Holdings Corporation15.5.2026 18:15:00 CEST | Press release

STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has acquired a significant ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515594020/en/ As of the date of this release, STARTEEPO and its affiliates beneficially owns 6.6 million shares of Xerox (excluding options), representing approximately 5.05% of the Company’s outstanding common stock. STARTEEPO has filed a Schedule 13D with the U.S. Securities and Exchange Commission (the “SEC”) providing additional details regarding its investment. Investment Perspective STARTEEPO believes that Xerox represents an interesting investment opportunity supported by a combination of balance sheet initiatives, ongoing operational improvements, and its position within a changing and consolidating industry. In STARTEEPO’s view, the Company

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye